Journal article

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Abstract:: Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2.
Methods We did a phase 1/2, single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., Dold, C., Faust, S. N., Finn, A., Flaxman, A. L., Hallis, B., Heath, P., Jenkin, D., Lazarus, R., Makinson, R., … Group, O. C. O. V. I. D. V. T. (2020). Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, 396(10249), 467–478.

MLA Style

Folegatti, P. M., et al. “Safety and Immunogenicity of the ChAdOx1 NCoV-19 Vaccine against SARS-CoV-2: a Preliminary Report of a Phase 1/2, Single-Blind, Randomised Controlled Trial.” Lancet, vol. 396, no. 10249, Elsevier, 2020, pp. 467–78.

Chicago Style

Folegatti, PM, KJ Ewer, PK Aley, B Angus, S Becker, S Belij-Rammerstorfer, D Bellamy, et al. 2020. “Safety and Immunogenicity of the ChAdOx1 NCoV-19 Vaccine against SARS-CoV-2: a Preliminary Report of a Phase 1/2, Single-Blind, Randomised Controlled Trial.” Lancet 396 (10249): 467–78.
Share
Print

Access Document

Files:: 1-s2.0-S0140673620316044-main.pdf

(Preview, Version of record, 2.6MB, Terms of use)

1-s2.0-S0140673620316871-main.pdf

(Preview, Version of record, 47.3KB, Terms of use)

Publisher copy:: 10.1016/S0140-6736(20)31604-4

Authors

+ Folegatti, PM More by this author

Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author

+ Ewer, KJ More by this author

Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author

+ Aley, PK More by this author

Division:: MSD
Department:: NDM
Sub department:: Paediatrics
Role:: Author

+ Angus, B More by this author

Division:: MSD
Department:: NDM
Role:: Author

+ Becker, S More by this author

Role:: Author

More authors...

Contributors

Division:: MSD
Department:: NDM
Sub department:: NDM Experimental Medicine
Role:: Contributor
ORCID:: 0000-0002-0895-3442

Publisher:: Elsevier
Journal:: Lancet More from this journal
Volume:: 396
Issue:: 10249
Pages:: 467-478
Publication date:: 2020-07-20
Acceptance date:: 2020-07-20
DOI:: 10.1016/S0140-6736(20)31604-4
ISSN:: 0140-6736

Language:: English
Pubs id:: 1120496
Local pid:: pubs:1120496
Deposit date:: 2020-07-20

Terms of use

Copyright holder:: Folegatti et al.
Copyright date:: 2020
Rights statement:: © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license
Notes:: A correction to this article is available at:
https://doi.org/10.1016/S0140-6736(20)31687-1

Licence:: CC Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP